E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Blood loss in patients undergoing elective total hip or knee arthroplasty. |
|
E.1.1.1 | Medical condition in easily understood language |
Blood loss in patients undergoing planned total hip or knee replacement surgery. |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10053220 |
E.1.2 | Term | Hip injury |
E.1.2 | System Organ Class | 100000004863 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10049032 |
E.1.2 | Term | Knee injury |
E.1.2 | System Organ Class | 100000004863 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the efficacy of two different dosing regimens of intravenous Tranexamic Acid during total hip or knee arthroplasty by assessing the total perioperative blood loss from start of surgery until 24 hours after end of surgery. |
|
E.2.2 | Secondary objectives of the trial |
To measure plasma concentrations of TXA will be at 7 different times using ultra-high performance liquid chromatography. Further the correlation of different plasma concentrations of TXA with POC testing of TXA activity, based on EMT using ClotPro, will be assessed. At the same timepoints we will conduct thrombin generation testing. We also assess the total number of units of red blood cells transfused and the occurrence of cardiovascular (e.g. myocardial infarction, thromboembolic events) and neurologic complications (e.g. seizures) from the beginning of TXA administration until 48 h after termination of the continuous TXA infusion. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Undergoing elective total hip or knee arthroplasty under general anaesthesia • Age ≥ 18 years • Written informed consent given |
|
E.4 | Principal exclusion criteria |
• Allergy to Tranexamic Acid • Acute venous or arterial thrombosis (eg. myocardial infarction, stroke) within the past six months • Renal impairment (eGFR <60 ml/min/1.73 m2) • Untreated or not sufficient treatable convulsions • Pregnancy • Patient not able to understand study procedures |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Total perioperative blood loss in millilitre blood. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1. Difference of haemoglobin levels before surgery and 24h after surgery (analysed by an ANCOVA- model). 2. Total amount of units of red blood cells transfused 3. Complications (cardiovascular complications + neurological complications). 4. Plasma Tranexamic Acid concentrations at different timepoints. 5. Results of EMT – ClotPro at the same timepoints 6. Results of ROTEM at the same timepoints 7. Thrombin generation at the same timepoints 8. The correlation of plasma Tranexamic Acid Concentrations and ClotPro/ROTEM results 9. Correlation of plasma Tranexamic Acid Concentrations and Thrombin generation
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Before administration of the TXA bolus dose 2. Immediately (within 5 minutes) after completion of the bolus administration of TXA 3. 1.5 hours after completion of the bolus administration of TXA 4. 5 minutes after the completion of surgery, defined by skin closure 5. 2 hours after termination of the continuous infusions of TXA 6. 24 hours after termination of the continuous infusions of TXA 7. 48 hours after termination of the continuous infusions of TXA |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS One interim analysis is planned, using the O’Brien and Fleming procedure. If the group comparison reveals a significant result, with the primary endpoint as dependent variable, the study goal is reached and the patient recruitment will be stopped. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | |